Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption

Circulation. 2003 Jul 1;107(25):3124-8. doi: 10.1161/01.CIR.0000072345.98581.24.
No abstract available

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adolescent
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / pharmacology
  • Anticholesteremic Agents / therapeutic use*
  • Azetidines / adverse effects
  • Azetidines / pharmacology
  • Azetidines / therapeutic use*
  • Cholesterol / metabolism*
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / drug effects
  • Clinical Trials as Topic / statistics & numerical data
  • Ezetimibe
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / drug therapy*
  • Intestinal Absorption / drug effects*
  • Male
  • Middle Aged
  • Myocardial Infarction / complications
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / prevention & control
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Cholesterol
  • Ezetimibe